Charles Afram, MSc, BSc, studied Molecular Biology at the Vrije Universiteit in Amsterdam, The Netherlands and Biological Sciences at the Kwame Nkrumah’ University of Science and Technology, Kumasi, Ghana.
He is a partner at OncoNeth Partners and a medical advisor oncology for the Nordic Pharma Group, a pan-European pharmaceutical company, where he focuses his activities on a selected number of therapeutic areas with significant unmet medical needs, including Oncology and Hematology.
As a medical advisor, Afram has over 13 years experience in the pharmaceutical industry, including medical information, medical management, drug safety and regulatory affairs. Before joining Nording Pharma in 2012, he was a clinical project manager at Bhoeringer Ingelheim and worked at companies including Celgene, Roche, Novo Nordisk and Amgen in regulatory, medical and drug safety management.
Last Editorial Review: March 15, 2015
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.